Regeneron’s cemdisiran enters FDA and EMA review for generalized myasthenia gravis
Find out how Regeneron’s cemdisiran review could reshape generalized myasthenia gravis care with potential quarterly subcutaneous dosing.
Pharma & Biotech
Pharma & Biotech
Parabilis Medicines IPO boom raises the bar for zolucatetide clinical execution
Find out how Parabilis Medicines’ IPO surge could reshape investor appetite for Helicon peptides and Wnt-driven oncology drugs.
Pharma & Biotech
Regeneron’s $2.2bn Parabilis pact signals rising interest in next-generation conjugates
ADCs changed cancer delivery. Regeneron and Parabilis now want Helicon peptides to push conjugates inside harder-to-drug biology.
Pharma & Biotech
Can Regeneron Pharmaceuticals redefine allergy treatment with Phase 3 allergen-blocking antibodies and Dupilumab expansion
Find out how Regeneron Pharmaceuticals’ AAAAI 2026 data could reshape allergy treatment strategies and regulatory expectations.